Pramipexole in treatment-resistant depression: An extended follow-up
โ Scribed by Paolo Cassano; Lorenzo Lattanzi; Federico Soldani; Serena Navari; Giulia Battistini; Alfredo Gemignani; Giovanni Battista Cassano
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- English
- Weight
- 93 KB
- Volume
- 20
- Category
- Article
- ISSN
- 1091-4269
- DOI
- 10.1002/da.20038
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
## Introduction: In patients with bipolar disorder, relapse and recurrence from the premature discontinuation of pharmacotherapy are serious clinical problems. thus, clinicians must make every effort to ensure the sufficient duration of continual treatment even after the remission of acute episodes
Drug resistant depression is a confounding entity. More so in populations of elderly depressives where addition of lithium or antidepressant combinations are possibly hazardous. We present an open-trial of thyroxine in elderly patients diagnosed as suffering from resistant depression. Methods -Thyro
In this paper we extend and test with long-term follow-up the results of a previous paper on the usefulness of a sequential treatment protocol with risperidone and clozapine in resistant schizophrenia. Twenty-four patients diagnosed as resistant schizophrenics according to DSM III R and Kane et al.
for the Brazilian Wilms' Tumor Study Group$ Background. To verify the adequacy of a simplified chemotherapeutic regimen for the treatment of Wilms' tumor (WT), the authors conducted a clinical trial to compare the standard fractionated dose (15 mcg/kg x 5 days) of dactinomycin (AMD) with a single do